U.S. FDA declines to approve Vanda's stomach paralysis drug

(Reuters) - The U.S. Food and Drug Administration has declined to approve Vanda (NASDAQ:VNDA ) Pharmaceuticals' drug to treat stomach paralysis symptoms, the company said on Thursday.

Shares of the company fell about 14% to $4.26 in premarket trading.

Vanda was seeking the health regulator's nod for the drug tradipitant to treat gastroparesis, a condition characterized by delayed gastric emptying.

The disease is associated with symptoms such as severe nausea, vomiting, and difficulty finishing a normal meal.

Vanda licensed tradipitant from Eli Lilly (NYSE:LLY ) and is also studying it for motion sickness.



The health regulator had imposed a partial clinical hold on tradipitant, preventing trials longer than 12 weeks.

The company plans to submit a separate application for the drug to prevent vomiting in motion sickness later this year.

Source: Investing.com